The 36th Annual General Meeting is scheduled to be held on Tuesday, September 23, 2025 at 11.30 AM through VC/OAVM. Plesae find the Annual Report for the FY 2024-25 containing notice of the AGM.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pharmaids Pharmaceuticals has scheduled its 36th AGM for September 23, 2025 at 11:30 AM via video conferencing, with e-voting open from September 19 to September 22, 2025. The company's standalone revenue grew sharply to Rs. 335.98 Lakhs in FY25 from Rs. 82.27 Lakhs in FY24, while consolidated revenue rose to Rs. 1,955.14 Lakhs from Rs. 1,599.03 Lakhs. However, losses widened — standalone net loss of Rs. 727.92 Lakhs and consolidated net loss of Rs. 1,350.51 Lakhs — and no dividend was declared. Key developments during the year include the approval to sell 3.45 acres of land in Tumkur to the Chairman for Rs. 16.5 Cr, an open offer that completed in August 2025 leading to a change in management control, and the sale of the Anugraha Chemicals partnership stake for Rs. 10.5 Cr to improve liquidity. The company is also pursuing a transition into a Contract Research, Development and Manufacturing Organization (CRDMO).
Shareholders should note the wider losses despite revenue growth, reflecting the company is still in a heavy investment and transition phase. The asset sales and management change are aimed at improving liquidity and focusing on the CRDMO strategy, which could be positive long-term but signals short-term financial stress.